Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)

https://ift.tt/JzVhxu4

Dupixent^® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)

from Sanofi - Aventis Groupe https://ift.tt/Bs10RSb
via IFTTT

" May good health envelop you, spurring a quick recovery. .. "

from health care https://ift.tt/jFlGywJ
via IFTTT https://ift.tt/IcY7MmA